로딩 중…
지수 로딩 중…
HK inno.N Corporation
195940· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩34,700-3.61%
2026-10-15
Financials
Valuation Metrics
HK inno.N Corporation's Market Cap is ₩9830B. At end of 2025 it was ₩1.4T. Ranked #299 of 2,414 in KR market (top 12%), #81 of 1,633 on KOSDAQ (top 5%), #33 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 14%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 983.05B KRW | KR#299/2,414 Sec#33/231 |
| Revenue | 1.08T KRW | KR#390/2,414 Sec#12/231 |
| Net Income | 85.85B KRW | KR#275/2,414 Sec#15/231 |
| Total Assets | 2.02T KRW | KR#305/2,414 Sec#12/231 |
| Net Assets | 1.35T KRW | KR#234/2,414 Sec#11/231 |
| Employees | 1,721 | KR#161/2,414 Sec#8/231 |
| Value | ||
| P/E | 11.45x | KR#930/2,414 Sec#48/231 |
| P/B | 0.73x | KR#1,206/2,414 Sec#66/231 |
| PEG | 0.32x | KR#648/2,414 Sec#38/231 |
| P/S | 0.91x | KR#1,359/2,414 Sec#77/231 |
| EV/EBITDA | 10.42x | KR#671/2,414 Sec#31/231 |
| FCF Yield | 8.90% | KR#665/2,414 Sec#30/231 |
| Profitability | ||
| ROE | 6.36% | KR#945/2,414 Sec#66/231 |
| ROA | 4.24% | KR#826/2,414 Sec#66/231 |
| Op. Margin | 11.98% | KR#423/2,414 Sec#36/231 |
| Revenue Growth | 10.55% | KR#869/2,414 Sec#83/231 |
| Earnings Growth | 35.95% | KR#616/2,414 Sec#40/231 |
| Financial Health | ||
| Debt Ratio | 49.74% | KR#957/2,414 Sec#110/231 |
| Total Debt | 430.80B KRW | KR#335/2,414 Sec#11/231 |
| FCF | 87.49B KRW | KR#215/2,414 Sec#12/231 |
| Cash | 68.25B KRW | KR#617/2,414 Sec#32/231 |
| Current Ratio | 0.89x | KR#1,846/2,414 Sec#179/231 |
| Net Debt/EBITDA | 2.81x | KR#902/2,414 Sec#65/231 |
| Dividend | ||
| Div. Yield | 1.18% | KR#1,090/2,414 Sec#63/231 |
| Div. Growth | 17.14% | KR#483/2,414 Sec#27/231 |
| Performance | ||
| 1Y Return | -26.64% | KR#1,358/2,414 Sec#100/231 |
| 1M Return | -12.15% | KR#1,728/2,414 Sec#173/231 |
| From 52W High | -40.78% | KR#819/2,414 Sec#59/231 |
| 1Y MDD | -39.76% | KR#580/2,414 Sec#39/231 |
| Trading | ||
| Volume | 111,328 shares | KR#877/2,414 Sec#85/231 |
| Trading Value | 3.86B KRW | KR#431/2,414 Sec#38/231 |
| Foreign Own. | 11.94% | KR#416/2,414 Sec#33/231 |
| Per Share | ||
| EPS | 3,030 KRW | KR#337/2,414 Sec#21/231 |
| BPS | 47,678 KRW | KR#273/2,414 Sec#18/231 |
Company Info
동사는 2014년 씨제이제일제당㈜의 제약사업부문 물적분할로 설립되어 2018년 한국콜마㈜에 인수됨. 전문의약품 제조판매업 등 ETC사업부문과 음료수 제조업 등 H&B사업부문으로 구분되며, 다양한 의약품과 원료의약품을 국내외 판매하고 있음. 신약 케이캡, 로바젯 등 핵심 제품을 보유하고 있으며, 암, 소화, 당뇨 같은 혁신적 파이프라인을 확보하며 발전시키고 있음. HK이노엔는 2014년에 설립되었으며 충청북도 청주시에 본사를 두고 있습니다.